http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2464041-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4cf3c1aa72c8378239f3e5d59bfb66b7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2007-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9a6049b8e3b3aaefef4d2f5881bb25b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_643f2ee6d08a67278100b9a2bc9e247b |
| publicationDate | 2012-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2464041-C2 |
| titleOfInvention | Use of cd 151 antibodies for treating cancer |
| abstract | FIELD: medicine. n SUBSTANCE: group of inventions refers to medicine, more specifically to oncology, and concerns the use of CD151 antibodies for treating primary tumours. What is offered is the use of at least one antibody or one of its functional fragments able to bind to CD151 protein and to inhibit tumour cell growth for preparing a therapeutic agent for treating primary tumours. There are also presented a composition for treating primary tumours containing said antibody or its functional fragment as an active principle, and the use of said composition for preparing the drug for treating primary tumours. In a particular case, the CD151 antibody represents a monoclonal TS151 or TS 151r antibody. n EFFECT: group of inventions provides the new therapeutic agent for treating primary tumours possessing an ability to inhibit developing tumours at the early stages. n 20 cl, 9 dwg, 5 tbl, 7 ex |
| priorityDate | 2006-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 357.